[pending] LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
Pending LLM rewrite. Source: FDA_DRUG D-0145-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules.
The recalled product
- Product
- LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
- Brand
- LISDEXAMFETAMINE DIMESYLATE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: AD42469
- Expiry: 2/28/2026
- AD48707
- Expiry:4/30/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LISDEXAMFETAMINE DIMESYLATE
- HighPrescription Drug Lisdexamfetamine Dimesylate Recalled for Failed Content Uniformity
FDA (Drugs) · 2024-12-11
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateGasco Isopropyl Alcohol 70% recalled nationwide for subpotency
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- ModerateGasco Isopropyl Alcohol 70% recalled for subpotent drug content
FDA (Drugs) · 2026-07-15